Peptide catalog DOTA peptides represent a sophisticated class of molecules that are revolutionizing medical diagnostics and therapeutics, particularly in the field of oncology. These compounds combine the targeting capabilities of peptides with the strong metal-chelating properties of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). This powerful conjugation allows for the precise delivery of radionuclides to specific biological targets, enabling highly effective imaging and treatment of various diseases, most notably neuroendocrine tumors and other cancers. The development and application of DOTA-peptides are central to advancements in personalized medicine, offering new avenues for disease detection, staging, and targeted therapy.Solid-Phase Synthesis of DOTA-Peptides
The core utility of DOTA peptides lies in their ability to form stable complexes with a wide range of medically relevant metal isotopes. The DOTA molecule acts as a cage, securely binding to radionuclides such as Gallium-68 (⁶⁸Ga) for Positron Emission Tomography (PET) imaging, or Lutetium-177 (¹⁷⁷Lu) and Yttrium-90 (⁹⁰Y) for therapeutic applications in Peptide Receptor Radionuclide Therapy (PRRT). This precise radiolabeling is crucial for both diagnostic accuracy and therapeutic efficacy, ensuring that the radionuclide is delivered directly to the intended site with minimal off-target exposure.
DOTA, a macrocyclic chelator, is exceptionally adept at forming highly stable complexes with metal ions. Its structure provides multiple coordination sites, which are essential for encapsulating radionuclides securely.作者：N Alexander·2018·被引用次数：50—Radiolabeled DOTA-peptides areused routinely in adults to image neuroendocrine tumorsand have potential to be used to image and treat neuroblastoma. When coupled with specific peptides, DOTA acts as a bifunctional linker, allowing the peptide to bind to its target receptor while the DOTA moiety carries the radionuclide....peptides(37)(38)(39). TheDOTAmonoamide conjugatedpeptide[Tyr 3 ]-octreotide (DOTA-TOC) (Fig. 6) showed very promising in vivo and in vitro properties ... This strategic pairing is fundamental to the development of agents like DOTATATE and DOTATOC, which target somatostatin receptors often overexpressed on neuroendocrine tumors.
The synthesis of DOTA-peptide conjugates involves intricate chemical processes. Solid-phase synthesis is a common methodology that allows for the controlled and versatile introduction of DOTA into peptide sequences. This approach facilitates the creation of custom DOTA-peptides tailored for specific diagnostic or therapeutic purposesDOTA/NOTA functionalization. Researchers continuously refine these labeling procedures of DOTA-peptides to optimize reaction kinetics, yield, and the purity of the final radiolabeled product. Ensuring high radiochemical purity and specific activity is paramount for reliable clinical outcomes作者：WAP Breeman·2014—RadiolabelledDOTA-peptidesare in use for Peptide Receptor Radionuclide Scintigraphy (PRS) and Therapy (PRRT), e.g with177Lu-DOTA-TATE or90Y-DOTATOC..
In diagnostic imaging, DOTA peptides are primarily used with positron-emitting radionuclides like ⁶⁸Ga.The Synthesis and Chelation Chemistry of DOTA−Peptide ... The resulting ⁶⁸Ga-labeled DOTA-peptides are invaluable for PET imaging, offering high sensitivity and resolution for visualizing receptor-mediated processes.DOTATATE acetate | DOTA-Conjugated Peptide A prominent example is their use in imaging neuroendocrine tumors (NETs). By targeting somatostatin receptors, these radiotracers enable the visualization and quantification of receptor expression across the body, providing critical insights into tumor biology, receptor status, and guiding treatment decisions. The ability to perform PET/CT with 68Gallium-DOTA-peptides has significantly improved the detection and management of NETs, allowing for more precise staging and monitoring of treatment response.
Beyond NETs, research is exploring the potential of DOTA-peptides for imaging other cancer types, such as neuroblastoma. The development of novel DOTA-peptide conjugates targeting different receptors is an ongoing area of research, aiming to expand the diagnostic utility of this technology....peptides(37)(38)(39). TheDOTAmonoamide conjugatedpeptide[Tyr 3 ]-octreotide (DOTA-TOC) (Fig. 6) showed very promising in vivo and in vitro properties ...
The therapeutic potential of DOTA peptides is realized through Peptide Receptor Radionuclide Therapy (PRRT). In this approach, DOTA-peptides are labeled with therapeutic beta-emitting or alpha-emitting radionuclides, such as ¹⁷⁷Lu or ⁹⁰Y. These radiolabeled peptides then bind to target receptors on cancer cells, delivering a cytotoxic radiation dose directly to the tumor.
¹⁷⁷Lu-DOTATATE, for instance, has emerged as a significant treatment option for patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors. This therapy leverages the high avidity of somatostatin receptors on these tumors to deliver targeted radiation, leading to tumor regression and improved patient survival. The stability of the DOTA chelate is crucial here, ensuring that the therapeutic radionuclide remains bound to the peptide throughout its journey to the tumor and during its therapeutic action.177Lu-DOTATATE for the treatment of gastroenteropancreatic ...
The efficacy of PRRT also depends on optimizing labeling procedures of DOTA-peptides and ensuring consistent quality controlEdotreotide is a substance which, when bound to various radionuclides,is used in the treatment and diagnosis of certain types of cancer.. Factors such as the specific activity, incorporation yield, and radiochemical purity of the final labeled peptides are rigorously assessed to guarantee the safety and effectiveness of the treatment.
Despite the significant progress, challenges remain in the field of DOTA peptides. Optimizing synthesis and labeling protocols for various radionuclides and peptide sequences is an ongoing endeavor. Furthermore, understanding the pharmacokinetics and dosimetry of these agents is crucial for personalized treatment planning...peptides(37)(38)(39). TheDOTAmonoamide conjugatedpeptide[Tyr 3 ]-octreotide (DOTA-TOC) (Fig. 6) showed very promising in vivo and in vitro properties .... Research is also focused on developing new DOTA-peptide conjugates with improved targeting specificity and therapeutic indices for a broader range of cancers. The exploration of alpha-emitters with DOTA conjugates also holds promise for more potent targeted therapies. As the field evolves, DOTA peptides are poised to play an even more significant role in precision medicine, offering advanced diagnostic and therapeutic solutions.
Join the newsletter to receive news, updates, new products and freebies in your inbox.